Evidence map›Paper›PMID 38782810›Full record

ArticleJournal of general internal medicine2024

The State of Hepatitis C Elimination from the Front Lines: A Qualitative Study of Provider-Perceived Gaps to Treatment Initiation.

Christopher J Gonzalez, Shashi N Kapadia, Jeff Niederdeppe, Arpan Dharia, Andrew H Talal, Audrey R Lloyd, Ricardo Franco, Stephane Labossiere, Martin F Shapiro, Elaine Wethington

Abstract read
In one paragraph

Article in Journal of general internal medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Christopher J GonzalezDivision of General Internal Medicine, Department of Medicine, Weill Cornell Medicine, New York, NY, USA. cjg7003@med.cornell.edu.ORCID 0000-0003-2916-4175
Shashi N KapadiaDivision of Infectious Diseases, Weill Cornell Medicine, New York, NY, USA.
Jeff NiederdeppeCornell Jeb E. Brooks School of Public Policy and Department of Communication, Cornell University, Ithaca, NY, USA.
Arpan DhariaDivision of Gastroenterology, Hepatology and Nutrition, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.
Andrew H TalalDivision of Gastroenterology, Hepatology and Nutrition, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.
Audrey R LloydDepartment of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA.
Ricardo FrancoDepartment of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA.
Stephane LabossiereDepartment of Health Studies & Applied Educational Psychology, Columbia University, New York, NY, USA.
Martin F ShapiroDivision of General Internal Medicine, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Elaine WethingtonDepartment of Psychology, College of Human Ecology, Cornell University, Ithaca, NY, USA.

Funding

Disparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods StudyR01DK123205 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI SHAPIRO, MARTIN F. · 2020 to 2024
$3.1M
Integrated Care for Hepatitis C: Current Uptake & Impact on Future TreatmentK01DA048172 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI KAPADIA, SHASHI · 2019 to 2023
$948k
NIDA NIH HHS K01 DA048172NIDA NIH HHS K01DA048172NIDDK NIH HHS R01 DK123205NIDDK NIH HHS R01DK123205Patient-Centered Outcomes Research Institute IHS-1507-31640
6 · The paper itself

Abstract

backgroundHepatitis C (HCV) is a curable chronic infection, but lack of treatment uptake contributes to ongoing morbidity and mortality. State and national strategies for HCV elimination emphasize the pressing need for people with HCV to receive treatment.

objectiveTo identify provider-perceived barriers that hinder the initiation of curative HCV treatment and elimination of HCV in the USA. APPROACH: Qualitative semi-structured interviews with 36 healthcare providers who have evaluated patients with HCV in New York City, Western/Central New York, and Alabama. Interviews, conducted between 9/2021 and 9/2022, explored providers' experiences, perceptions, and approaches to HCV treatment initiation. Transcripts were analyzed using hybrid inductive and deductive thematic analysis informed by established health services and implementation frameworks. KEY

resultsWe revealed four major themes: (1) Providers encounter professional challenges with treatment provision, including limited experience with treatment and perceptions that it is beyond their scope, but are also motivated to learn to provide treatment; (2) providers work toward building streamlined and inclusive practice settings-leveraging partnerships with experts, optimizing efficiency through increased access, adopting inclusive cultures, and advocating for integrated care; (3) although at times overwhelmed by patients facing socioeconomic adversity, increases in public awareness and improvements in treatment policies create a favorable context for providers to treat; and (4) providers are familiar with the relative advantages of improved HCV treatments, but the reputation of past treatments continues to deter elimination.

conclusionsTo address the remaining barriers and facilitators providers experience in initiating HCV treatment, strategies will need to expand educational initiatives for primary care providers, further support local infrastructures and integrated care systems, promote public awareness campaigns, remove prior authorization requirements and treatment limitations, and address the negative reputation of outdated HCV treatments. Addressing these issues should be considered priorities for HCV elimination approaches at the state and national levels.

Indexed as

Qualitative ResearchAdultAlabamaAntiviral AgentsAttitude of Health PersonnelDisease EradicationFemaleHealth PersonnelHealth Services AccessibilityHepatitis CHepatitis C, ChronicHumansMaleMiddle AgedNew York CityAntiviral Agentsbarrierseliminationhepatitis Cproviderstreatment initiation

Identifiers

PMID38782810
PMCPMC11347520

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.